CANDEL THERAPEUTICS INC (CADL) Fundamental Analysis & Valuation

NASDAQ:CADL • US1374041093

Current stock price

4.995 USD
+0.03 (+0.5%)
Last:

This CADL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CADL Profitability Analysis

1.1 Basic Checks

  • CADL had negative earnings in the past year.
  • CADL had a negative operating cash flow in the past year.
  • In the past 5 years CADL always reported negative net income.
  • CADL had a negative operating cash flow in each of the past 5 years.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -30.50%, CADL is in the better half of the industry, outperforming 66.09% of the companies in the same industry.
  • CADL has a Return On Equity of -73.54%. This is comparable to the rest of the industry: CADL outperforms 52.79% of its industry peers.
Industry RankSector Rank
ROA -30.5%
ROE -73.54%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CADL Health Analysis

2.1 Basic Checks

  • CADL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CADL has more shares outstanding
  • Compared to 1 year ago, CADL has a worse debt to assets ratio.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 0.22, we must say that CADL is in the distress zone and has some risk of bankruptcy.
  • CADL has a Altman-Z score of 0.22. This is in the better half of the industry: CADL outperforms 60.89% of its industry peers.
  • CADL has a Debt/Equity ratio of 0.91. This is a neutral value indicating CADL is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.91, CADL is doing worse than 73.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z 0.22
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • CADL has a Current Ratio of 13.49. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
  • CADL's Current ratio of 13.49 is amongst the best of the industry. CADL outperforms 89.21% of its industry peers.
  • CADL has a Quick Ratio of 13.49. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
  • CADL has a Quick ratio of 13.49. This is amongst the best in the industry. CADL outperforms 89.21% of its industry peers.
Industry RankSector Rank
Current Ratio 13.49
Quick Ratio 13.49
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CADL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.95% over the past year.
EPS 1Y (TTM)59.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CADL will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.34% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.8%
EPS Next 2Y14.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 500M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. CADL Valuation Analysis

4.1 Price/Earnings Ratio

  • CADL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CADL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CADL's earnings are expected to grow with 14.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.34%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CADL Dividend Analysis

5.1 Amount

  • CADL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CADL Fundamentals: All Metrics, Ratios and Statistics

CANDEL THERAPEUTICS INC

NASDAQ:CADL (3/23/2026, 2:04:51 PM)

4.995

+0.03 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)03-26
Inst Owners32.66%
Inst Owner Change2.3%
Ins Owners11.8%
Ins Owner Change0%
Market Cap365.88M
Revenue(TTM)N/A
Net Income(TTM)-38.18M
Analysts82.86
Price Target19 (280.38%)
Short Float %20.52%
Short Ratio12.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.27%
Min EPS beat(2)-115.33%
Max EPS beat(2)-11.2%
EPS beat(4)2
Avg EPS beat(4)16.01%
Min EPS beat(4)-115.33%
Max EPS beat(4)142.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-53.43%
EPS NQ rev (3m)-53.43%
EPS NY rev (1m)-47.69%
EPS NY rev (3m)-50.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.05
P/tB 7.05
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS0.71
TBVpS0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.5%
ROE -73.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.49
Quick Ratio 13.49
Altman-Z 0.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35%
EPS Next Y13.8%
EPS Next 2Y14.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.58%
EBIT Next 3Y-5.1%
EBIT Next 5Y83.51%
FCF growth 1Y22.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.09%
OCF growth 3YN/A
OCF growth 5YN/A

CANDEL THERAPEUTICS INC / CADL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CANDEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CADL.


Can you provide the valuation status for CANDEL THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CANDEL THERAPEUTICS INC (CADL). This can be considered as Overvalued.


What is the profitability of CADL stock?

CANDEL THERAPEUTICS INC (CADL) has a profitability rating of 1 / 10.